De Novo and Recurrence of Nonalcoholic Steatohepatitis After Liver Transplantation

Matthew Kappus; Manal Abdelmalek

doi:10.1016/j.cld.2016.12.006

De Novo and Recurrence of Nonalcoholic Steatohepatitis After Liver Transplantation

Clin Liver Dis. 2017 May;21(2):321-335. doi: 10.1016/j.cld.2016.12.006. Epub 2017 Feb 1.

Authors

Matthew Kappus¹, Manal Abdelmalek²

Affiliations

¹ Division of Gastroenterology, Duke University Medical Center, 40 Duke Medicine Circle, PO Box 3913, Durham, NC 27710, USA.
² Division of Gastroenterology, Duke University Medical Center, 40 Duke Medicine Circle, PO Box 3913, Durham, NC 27710, USA. Electronic address: manal.abdelmalek@duke.edu.

PMID: 28364816
DOI: 10.1016/j.cld.2016.12.006

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in developing countries. Approximately 25% of patients with NAFLD develop nonalcoholic steatohepatitis (NASH). NASH-related cirrhosis is now a leading listing indication for liver transplantation in the United States. Although posttransplant survival for NASH-related cirrhosis is comparable with that of other liver diseases, many patients have features of metabolic syndrome, which can contribute to a recurrence of NAFLD or NASH. This article reviews the epidemiology, pathophysiology, and treatment of de novo and recurrence of NASH after liver transplantation.

Keywords: Cryptogenic cirrhosis; Hyperlipidemia; Hypertension; Insulin resistance; Metabolic syndrome; Nonalcoholic fatty liver disease; Obesity.

Publication types

Review

MeSH terms

Global Health
Humans
Incidence
Liver Transplantation / adverse effects*
Non-alcoholic Fatty Liver Disease / epidemiology*
Non-alcoholic Fatty Liver Disease / etiology
Postoperative Complications*
Recurrence
Risk Factors